Skip to main content
Premium Trial:

Request an Annual Quote

Ohio State University to Offer Vermillion's SELDI-Based Homebrew TTP Dx

NEW YORK (GenomeWeb News) - Ohio State University will make available a SELDI-based hematology test made by Vermillion, the company said today.
 
Vermillion, formerly known as Ciphergen, said OSU will license the homebrew test for managing patients with the blood-clotting disorder thrombotic thrombocytopenic purpura. The test was co-developed with the school’s University Research Foundation.
 
The laboratory-developed test uses SELDI mass spectrometry to measure enzyme levels for “precise, quantitative and reproducible results” for TTP. OSU plans to make it available by the end of the month through its reference laboratory.
 
Financial terms of the agreement were not released.
 
TTP is a potentially lethal disorder caused by an enzymatic deficiency that causes platelet clumping and loss of red blood cells, which in turn can lead to neurological and nephrological abnormalities.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.